Kavango Resources Ben Turney gives operational update on successful 2023. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

TOP NEWS: GSK's Arexvy vaccine approved for adults over 60 in Japan

Mon, 25th Sep 2023 08:37

(Alliance News) - GSK PLC on Monday said the Japan Ministry of Health, Labour & Welfare has approved Arexvy for adults over 60.

Arexvy is a vaccine used for the prevention of respiratory syncytial virus, which affects the lungs and breathing passages.

This is the first time an RSV vaccine for older adults has been approved in Japan, GSK said. The approval has been granted based on data from the AReSVi-006 phase III vaccine efficacy trial.

According to the London-based pharmaceutical maker, RSV causes approximately 63,000 hospitalisations and 4,500 deaths in Japan every year.

Back in June, Arexvy became the first EU-backed vaccine against the respiratory syncytial virus for adults aged 60 and older after the European Commission authorised the jab, after also receiving approval in the US.

GSK Chief Scientific Officer Tony Wood said: "Arexvy is Japan's first approved RSV older adult vaccine, and is a major advance for public health with the potential to help protect around 43.5 million Japanese people aged 60 and older. Following key approvals in the US, EU, UK and Canada earlier this year, today's authorisation reinforces GSK's industry-leading vaccine portfolio."

Shares in GSK were up 0.5% at 1,534.60 pence each in London on Monday morning.

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Related Shares

More News
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help c...

5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline result...

27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a ph...

22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.